comprehensive -WSS

comprehensive

author：comprehensive 2025-09-29 13:30:57 - browse：6369

The Food and Drug Administration on Tuesday approved brexanolone, the first drug specifically targeted to treat postpartum depression — the most common complication of childbirth. Yet it’s a condition that often goes untreated because new mothers fear being stigmatized if they report symptoms.

Brexanolone is the first drug developed by and approved from Sage Therapeutics. The Cambridge, Mass.-based biotech company will market the new medicine under the brand name Zulresso.

“This approval is important for postpartum depression patients and it’s important for our company. It’s rare in your career when you can introduce a new medicine that is different from what’s out there,” said Sage CEO Jeff Jonas.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Gain of function research would be limited under House proposal

knowledge

WSS

Congress must reauthorize a committee to support older Americans

Abridge raises $150m as clinical notes automation market heats up

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Weight loss drugs aren’t covered by Obamacare. That may change

FDA warns medical device makers about rise in fabricated data

CRISPR pioneers react to Casgevy, first gene

leisure time

comprehensive

entertainment

Psychedelics group wrestles with new pharma identity

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

United colonoscopy coverage change 'may cost lives,' doctors say

Childhood cancer progress stalls for Black, Hispanic kids: Report

The cancer drug shortage isn’t new — and neither are the solutions

Ukraine seeks to reclaim its role as a hub for clinical trials

New air purifier tech could be key to improving indoor air quality

In 'major milestone,' FDA approves first cell therapy for solid tumors

How one medical school became remarkably diverse

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

hotspot

David Sabatini, ex

Wegovy, Zepbound and weight loss drugs that preserve muscle

Childhood cancer progress stalls for Black, Hispanic kids: Report

Surprise medical billing ban raises prices elsewhere

Weight loss drug costs may need more research, senator suggests

Medicare Advantage enrollment grows 7.1% to 33.4 million people

leisure time

leisure time

knowledge

focus